Login / Signup

Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides.

Lara DunganJean DunneMichael SavioMarianna KalasziMatt McElheronYvonne LynaghKate O'DriscollCarmel RocheAmmara QureshiBrendan CrowleyNiall ConlonHugh Kearney
Published in: Neurology(R) neuroimmunology & neuroinflammation (2024)
This study demonstrates how testing and recording the cellular response to EBNA-1 in pwMS may be beneficial. EBNA-1 stimulation of whole blood samples produced higher levels of IFN-γ and IL-2 in pwMS compared with controls and PWE. In addition, we show a differential effect of currently available DMTs on this response. The functional assay deployed uses whole blood samples with minimal preprocessing suggesting that employment as a treatment response measure in clinical trials targeting EBV may be possible.
Keyphrases
  • epstein barr virus
  • immune response
  • multiple sclerosis
  • diffuse large b cell lymphoma
  • clinical trial
  • dendritic cells
  • high throughput
  • cancer therapy
  • toll like receptor
  • drug delivery
  • phase ii
  • double blind